

Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE,

703, ASTER 7, SUPERTECH EMERALD COURT, SECTOR-93A, NOIDA-201304 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlab.com

Tel. 0120-2426900, 9412700300

9th August 2017

The Head-Listing Compliance

BSE Limited

PhirozeJeejeebhoy Towers

Dalal Street

Mumbai 400001

Scrip Code: 531207

Subject: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir:

We would like to inform that the Board of Directors in their meeting held today i.e. Wednesday, August 9, 2017, (commenced at 1:00 P.M. and concluded at 6:30 P.M.) has inter alia approved and passed the following resolutions:

1. Unaudited Standalone Financial Results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and period ended June 30, 2017.
2. Took note of the Limited Review Report as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
3. Took note of Statement of Investor Complaints/Grievances under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended June 30, 2017.
4. The Board has finalized the venue of Annual General Meeting to be held on 30th August, 2017 as **Emerald Club, Supertech Emerald Court, Sector 93A, Gautam Buddha Nagar, Noida - 201304.**

Kindly take the above information on your records.

Sincerely,

For Raymed Labs Limited

For RAYMED LABS LTD

Ajai Goyal

Ajai Goyal

Director

Whole Time Director

DIN: 02636418

**Add: 703 Aster 7, Supertech Emerald Court
Sector 93A, Noida 201304**

Life is Preciousand Raymed cares

Raymed Labs Limited

Regd. Office: 703 Aster 7, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh, CIN: L24111UP1992PLC014240
E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300

Annexure I to Regulation 33

Statement of Standalone Un-Audited Financial Results for the Quarter Ended on June 30, 2017

		Quarter Ended			Rs. in Lacs
Particulars		3 Months Ended 30-06-2017	Preceding 3 Months 31-03-2017	Corresponding 3 Months in the Previous Year Ended 30-06-2016	Previous Year Ended 31-03-2017
		Unaudited	Audited	Unaudited	Audited
I	Revenue from Operations				
	(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-
	(b) Other Operating Income	-	-	-	-
II	Other Income	0.30	0.30	0.30	1.20
III	Total Revenue (I+II)	0.30	0.30	0.30	1.20
IV	Expenses				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, Work-in-progress and stock-in-trade	-	-	-	-
	(d) Employee Benefits Expenses	0.23	0.23	0.59	1.22
	(e) Finance Costs	-	-	-	-
	(f) Depreciation and amortisation expense	0.17	0.05	0.22	0.71
	(g) Other expenses	0.42	0.38	0.40	1.97
	Total Expenses	0.81	0.66	1.21	3.91
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	(0.51)	(0.36)	(0.91)	(2.71)
VI	Exceptional Items	2.88	-	2.29	2.29
VII	Profit/(Loss) before extraordinary items and tax (V-VI)	(3.39)	(0.36)	(3.20)	(5.00)
VIII	Extraordinary items	-	-	-	-
IX	Profit/(Loss) before tax (VII-VIII)	(3.39)	(0.36)	(3.20)	(5.00)
X	Tax Expense				
	(1) Current tax	-	-	-	-
	(2) Deferred tax	-	-	-	-
XI	Net Profit/(Loss) for the period from continuing operations (IX-X)	(3.39)	(0.36)	(3.20)	(5.00)
XII	Profit/(Loss) from discontinuing operations before tax	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-
XIV	Profit/(Loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-
XV	Profit/(Loss) for period before Minority interest	-	-	-	-
	Share of profit/Loss of Associates	-	-	-	-
	Profit/(Loss) of Minority interest	-	-	-	-
XVI	Profit/(Loss) for the period (XI+XIV)	(3.39)	(0.36)	(3.20)	(5.00)
XVII	Paid-up share capital (Face Value of the share shall be indicated)	427.35	427.35	427.35	427.35
XVIII	Reserve excluding revaluation reserve as per balance sheet of previous accounting year	-	-	-	-
XIX	Earning Per Equity Share				
	(a) Basic	-0.079	-0.008	-0.075	-0.117
	(b) Diluted	-0.079	-0.008	-0.075	-0.117

Notes:

- 1 The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 09.08.2017. The Statutory Auditors have audited the above results.
- 2 Segment reporting as defined in Accounting Standard (AS-17) is not applicable since the entire operation of the company relates to only one segment.
- 3 In terms of Regulation 13(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, there were no investor complaint pending at the beginning of the quarter or lying unresolved at 30.06.2017.
- 4 The figures have been re-grouped/re-arranged wherever considered necessary.

For RAYMED LABS L...

Ajai Goyal
Whole Time Director
DIN: 02636418

Director

Add.: 703 Aster 7, Supertech Emerald Court, Sector 93A
Noida - 201304, Uttar Pradesh

Place: NOIDA
Date: 09-08-2017



A. Kay. Mehra & Co.

CHARTERED ACCOUNTANTS

114 (Basement), Mall Road, Kingsway Camp, Delhi-110009
Tel No. : 011-42461274, 9891295255, 9818708294
E-mail : akmca1969@gmail.com Website : www.akmca.in

Annexure V to Regulation 33

To
The Board of Directors
Raymed Labs Limited
703, Aster 7, Supertech Emerald Court,
Sector 93A, Noida- 201304

Limited Review Report for the quarter and period ended 30th June, 2017

We have reviewed the accompanying statement of unaudited financial results of **Raymed Labs Limited** for the period ended 30th June, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A Kay Mehra & Co.
Chartered Accountants
FRN 050004C



Deepak Suneja
(CA Deepak Suneja)
Partner
F.R.N. 050004C

Place: New Delhi
Date: August 9, 2017